Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

ssion (EC) also approved the use of Soliris(TM) (eculizumab) for the treatment of patients with PNH. Soliris is the first therapy approved in Europe for the treatment of PNH and was the first medicinal product to receive EU approval under the EMEA Accelerated Assessment Procedure.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." Two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing physicians will be enrolled in the Soliris Safety Registry which is part of a special risk management program that involves initial and continuing education and long-term monitoring for detection of new safety findings.

Please see full prescribing information at http://www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. The Company is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a w
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 The ... Growing ageing population and rise in the incidence of ... chronic wounds and in affordability of better quality of ... wound care market. Universal coverage of public health insurance ... would further stimulate demand. Based on the findings of ...
(Date:9/30/2014)... 2014 BioStructures, LLC has been awarded ... Tissue Banks (AATB), it was announced today by ... Accreditation follows an intensive nine-month process, including ... inspector.  It establishes that the level of medical, ... or exceeds the standards set by the AATB.  ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4China Wound Care Market 2China Wound Care Market 3Biostructures, LLC Earns AATB Accreditation 2
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... N.C. (PRWEB) September 30, 2014 The ... an option to help diabetics curb their sweet tooth, ... Nature this September, suggests that zero-calorie sweeteners ... type 2 diabetes. , The Weizmann Institute of ... they fed artificial sweeteners to mice, the mice developed ...
(Date:9/30/2014)... 2014 With the flu season ... every day, it’s a perfect time to announce ... system is an electro-static disinfectant delivery system that ... normally missed with spray-on disinfectant applicators. , The ... an electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... September 30, 2014 Two revolutionary procedures now ... treatment of gum disease a far less painful and ... , “If you’ve ever felt electric shock waves surge through ... a cold beverage, it’s possible you already know the impact ... is a general dentist in West Palm Beach, and a ...
Breaking Medicine News(10 mins):Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3
... and Bioengineering (NIBIB) Laboratory of Bioengineering and Physical Science ... visualize fine details of cell structure three-dimensionally in thick ... organized and how they function. The work is described ... Nature Methods . The new electron tomography ...
... , , ... GTIV ), a leading provider of comprehensive home health ... the Company,s Board of Directors: Philip R. Lochner, Jr., Sheldon ... appointments, Gentiva has re-established an independent majority on its Board ...
... - NUCRYST Pharmaceuticals, a developer and manufacturer of ... Wound Management division of Smith Nephew ... Flex3 and Acticoat(TM) Flex7. The Flex range is ... dressings with NUCRYST,s proprietary SILCRYST(TM) nanocrystalline silver coatings. ...
... , , NEW YORK, Sept. ... is hosting a kick off cocktail reception to announce its Second ... the National Football League. The main event, The Journey of ... Rock Cafe with actress Lorraine Bracco and comedian Penny Marshall serving ...
... CAMBRIDGE, Mass., Sept. 3 Satori Pharmaceuticals Incorporated ... disease, Parkinson,s disease, and other neurodegenerative disorders, today announced that ... its Board of Directors. , , "We ... to our board," said Dr. Jeffrey Ives, Satori CEO. ...
... , , MIAMI BEACH, ... Oprah have spent years yo-yo dieting, but would they work so ... the extra pounds? These days, Fat is Fabulous, with reality shows ... zaftig women competing in dance-offs, bringing in big ratings numbers for ...
Cached Medicine News:Health News:NIBIB scientists increase imaging efficiency in cell structure studies 2Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 2Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 3Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 4Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 5Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 6Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 2Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 3Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 4Health News:Brain Injury Association of New York State to Host Kick Off Cocktail Reception 2Health News:Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors 2Health News:Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors 3Health News:Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors 4Health News:85% of Single Men Would Date Heavy Women; 90% of Single Women Feel Men Can't See Past a Few Extra Pounds, States Date.com 2Health News:85% of Single Men Would Date Heavy Women; 90% of Single Women Feel Men Can't See Past a Few Extra Pounds, States Date.com 3Health News:85% of Single Men Would Date Heavy Women; 90% of Single Women Feel Men Can't See Past a Few Extra Pounds, States Date.com 4
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: